Posted: December 10, 2008

New European projects aims to accelerate micro- and nanotechnology companies

(Nanowerk News) The competitiveness of high-tech companies very much relies on short time-to-market, which can only be achieved by faster product engineering.
The European project CORONA meets this challenge – for three years, having started in July 2008, nine partners all along the value chain in micro- and nanotechnologies (MNT) strive for accelerating the businesses of European companies. Amongst others, the project shall support customer-lead multi-site product development and provide an access to a knowledge-base on design and processes as well as to information and communication technology infrastructure and tools.
Now the website corona-mnt.eu has been launched. It presents the objectives, benefits and the methodology of the project and will keep interested persons informed about the results. Furthermore, coming events presenting CORONA will be announced here.
CORONA was showcased for the first time at the medical suppliers’ fair COMPAMED from November 19 to 21 in Düsseldorf, Germany
CORONA is a NMP (Nanosciences, Nanotechnologies, Materials and new Production Technologies) project in the Seventh Framework Programme (FP7) funded by the European Commission. The CORONA consortium includes companies, partly small and medium-sized enterprises (SMEs), and institutes that contribute experience in design methodology and tools for micro- and nanotechnology, MNT production in various technological areas as well as networking and dissemination activities. Involved are:
  • IVAM e.V., Microtechnology Network, Dortmund, Germany
  • Coventor Sarl, Villebon sur Yvette, France
  • Elmos Advanced Packaging BV, Nijmegen, the Netherlands
  • Instytut Technologii Elektronowej, Warsaw, Poland
  • Process Relations GmbH, Dortmund, Germany
  • Theon Sensors SA, Athens, Greece
  • University of Cambridge, Cambridge, Great Britain
  • Universität Siegen, Siegen, Germany
  • X-FAB Semiconductor Foundries AG, Erfurt, Germany
  • Source: IVAM